Extensive data from numerous large-scale clinical trials have consistently underscored the effectiveness of SGLT2 inhibitors in reducing HHF and CV mortality among patients with both CKD and HFpEF [38,63-65]. This evidence concerns the gene SLC5A2 and chronic kidney disease.